Radiotherapy and Oncology 106 (2013) 124–129

Contents lists available at SciVerse ScienceDirect

Radiotherapy and Oncology

journal homepage: www.thegreenjournal.com

Functional imaging

Proton therapy radiation pneumonitis local dose–response in esophagus cancer patients

Alfredo E. Echeverria [a,c], Matthew McCurdy [a,c], Richard Castillo [a], Vincent Bernard [b], Natalia Velez Ramos [b], William Buckley [a], Edward Castillo [a], Ping Liu [a], Josue Martinez [a], Thomas Guerrero [a,*]

[a] The University of Texas M.D. Anderson Cancer Center, Houston; [b] The University of Puerto Rico, San Juan; [c] Baylor College of Medicine, Houston, USA

ARTICLE INFO

Article history:
Received 10 December 2011
Received in revised form 3 August 2012
Accepted 6 September 2012
Available online 2 November 2012

Keywords:
Radiation pneumonitis
Proton therapy
Positron emission tomography

ABSTRACT

Purpose: This study quantifies pulmonary radiation toxicity in patients who received proton therapy for esophagus cancer.
Materials/methods: We retrospectively studied 100 esophagus cancer patients treated with proton therapy. The linearity of the enhanced FDG uptake vs. proton dose was evaluated using the Akaike Information Criterion (AIC). Pneumonitis symptoms (RP) were assessed using the Common Toxicity Criteria for Adverse Events version 4.0 (CTCAEv4). The interaction of the imaging response with dosimetric parameters and symptoms was evaluated.
Results: The RP scores were: 0 grade 4/5, 7 grade 3, 20 grade 2, 37 grade 1, and 36 grade 0. Each dosimetric parameter was significantly higher for the symptomatic group. The AIC winning models were 30 linear, 52 linear quadratic, and 18 linear logarithmic. There was no significant difference in the linear coefficient between models. The slope of the FDG vs. proton dose response was 0.022 for the symptomatic and 0.012 for the asymptomatic ($p = 0.014$). Combining dosimetric parameters with the slope did not improve the sensitivity or accuracy in identifying symptomatic cases.
Conclusions: The proton radiation dose response on FDG PET/CT imaging exhibited a predominantly linear dose response on modeling. Symptomatic patients had a higher dose response slope.
 Radiotherapy and Oncology 106 (2013) 124–129

Thoracic radiotherapy injures portions of the lung that are not involved with cancer [1–5]. Proton therapy has been proposed as a modality with the potential to reduced normal tissue toxicity. This potential benefit of proton therapy comes from the Bragg peak, which allows the maximal dose to be concentrated to the target region with minimal exposure beyond [6]. This should allow for the development of radiation plans with an improved therapeutic index, an increased tumoricidal effect while reducing normal tissue toxicity [7,8]. Several studies have reported improvements of local control and disease-free survival with the use of proton therapy [9,10]. However, proton therapy involves several physical and technical uncertainties, including uncertainties regarding the damage it may cause to normal tissues [7,11–16]. Most toxicity reports in the literature rely on subjective toxicity assessment and correlations with parameters extracted from the treatment plans [17–20]. To date, there has not been an objective measurement of the normal human lung proton therapy dose response.

Radiation pneumonitis (RP) is the most severe complication that occurs following thoracic radiotherapy and is potentially fatal [21]. RP is an inflammatory reaction that takes place within lung tissue in response to radiation damage [22–24]. Pulmonary inflammatory processes can be imaged using [^{18}F]-fluorodeoxyglucose positron emission tomography (FDG PET) [25,26]. We previously utilized restaging FDG PET/Computed Tomography (FDG PET/CT) images to provide an objective and quantitative measurement of the radiation dose response of the lungs after thoracic X-ray radiotherapy [27–29]. We observed a linear relationship between the radiation dose and FDG pulmonary uptake for each individual [27]. We call the slope of this dose response the pulmonary metabolic radiation dose response (PMRR). We also found a statistically significant correlation between PMRR and RP clinical symptoms [28,29]. We used the PMMR to demonstrate an increased RP toxicity associated with the degree of taxane use [29].

Population studies of RP found dosimetric parameters, such as the mean lung dose (MLD), associate with the risk to develop symptomatic RP [30–32]. Methods to individualize the risk assessment by adjusting the probability of RP based on the odds ratio associated with the presence of dose-independent risk factors have been proposed [33]. However, the individual pulmonary RP dose–response for proton therapy is unknown. In a toxicity modeling study, Seppenwoolde et al. [35] found a linear local-dose response best explained the incidence of RP on the basis of the individual dose distributions. Knowledge of the individual RP dose–response

* Corresponding author. Address: Department of Radiation Oncology – Unit 97, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.
E-mail address: tguerrero@mdanderson.org (T. Guerrero).

0167-8140/$ - see front matter © 2012 Elsevier Ireland Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.radonc.2012.09.003

would guide treatment strategies, such as, whether a little dose to a large amount of lung or a high dose to small amount of lung is more critical for induction of RP [34]. Patients with esophageal cancer routinely undergo restaging FDG PET/CT 6 weeks after neoadjuvant chemoradiation therapy to identify interval metastases. Using the restaging FDG PET/CT imaging as a surrogate for the local dose RP response we found the local-dose response of the lungs is indeed linear for X-ray therapy [27].

In this retrospective study, the local pulmonary dose response relationship is evaluated on post-treatment FDG PET imaging in esophagus cancer patients who received proton therapy. We hypothesize the individual RP dose–response for proton radiation is linear with symptomatic patients possessing a more intense response.

Materials and methods

The study population comprised patients treated at the University of Texas M.D. Anderson Proton Therapy Center for esophagus cancer between July 12, 2006 and April 1, 2011 ($n = 100$) who had restaging PET/CT imaging between 21 and 86 days after completion of proton therapy. Proton beam treatment planning was performed using the Eclipse treatment planning system (Varian Medical Systems, Palo Alto, CA) and the radiation dose was calculated using the average CT obtained from 4D CT image sets. All proton therapy treatment plans were prospectively reviewed for quality assurance by 10 radiation oncologists who specialize in thoracic malignancies. Patient identifiers were removed in accordance with a retrospective study protocol (PA11-0801) approved by the M.D. Anderson Institutional Review Board.

Study subjects had FDG PET/CT images between 21 and 86 days after completion of radiotherapy for interval restaging evaluation [37]. Image analysis was performed using custom Matlab software (v2011a, Mathworks, Inc.). Lung segmentation was applied to the treatment planning CT and the restaging PET/CT images using Hounsfield units between −920 and −250 plus connectivity. Residual trachea, main stem bronchial, and second division bronchi were removed manually. The resulting binary lung regions of interest (lung ROI) were used in subsequent analyses. Mean lung dose (MLD), the volume of lung irradiated to 5, 10 and 20 CGE (V_5,V_{10},V_{20} respectively) were calculated and used as dosimetric parameters to estimate the effect from the lung volumes irradiated. The restaging FDG PET/CT images were spatially registered to the planning CT using an affine transformation. The transformation was derived from a set of (>1000) matched point pairs generated by an automated point matching algorithm [39] following the approach described by Ourselin et al. [40]. The image registrations were all visually verified for spatial accuracy.

The standard uptake values (SUV) were calculated from the PET attenuation corrected emission images. The mean SUV values in 10-CGE intervals over the dose ranges from 0 to 60 Cobalt-60 Gray equivalents (CGE) in the lung tissue were calculated for each case. The median of SUV mean values and the range of the means for the 100 cases were determined. The maximum SUV value within pulmonary tissue irradiated above 5 CGE was found for all 100 cases. Histograms, normalized by volume, were formed of the FDG PET uptake vs. radiation dose in 2-CGE intervals. SUV values within the lung were normalized to the un-irradiated lung ($\leqslant$2 CGE) [27]. A linear regression model was applied to the normalized [^{18}F]-FDG uptake for each case to obtain the PMRR. Deviation from the individual linear response was tested for each case.

To test the individual dose response linearity hypothesis multiple models were compared. A purely linear model was compared with models containing the additions of quadratic and logarithm functions of dose into the regression equations. The Akaike Information Criterion (AIC) goodness of fit statistic [41] was used to rate the models. For each model the AIC statistic was calculated as:

$$\mathrm{AIC} = -2 \times \log(\mathrm{MLE}) + 2 \times N_p, \quad (1)$$

where N_p is the number of independent parameters and MLE is the maximized value of the likelihood function for the estimated model. The model minimizing the AIC value provides the best balance between parsimony and goodness of fit. Next, the linear slopes were compared between strictly linear and the combined models.

The medical records were reviewed and scored for respiratory symptoms of pneumonitis using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4 (CTCAE v4). Briefly, the criteria for CTCAE v4 pneumonitis symptom scoring was: 0 – no signs or symptoms, 1 – diagnostic observations only, 2 – symptoms limiting instrumental activities of daily living (ADLs), 3 – severe symptoms limiting self care or oxygen indicated, 4 – life-threatening respiratory compromise (e.g. intubation), and 5 – death. All patient documents were used in the scoring until 6 months after completing radiation or until esophagectomy. The consensus of six clinicians was used for each score. Clinically symptomatic pneumonitis was defined as grade 2 or higher.

Continuous variables were summarized in the form of mean (SD, range). Categorical variables were summarized in the form of frequency tables. Analysis of variance was used to compare PMRR values across treatment groups. Logistic regression models were used to predict the toxicity outcome (Grade 2 or greater vs. Grade 0–1) according to MLD only, V20 only, PMRR only, both MLD and V20, both MLD and PMRR, and both V20 and PMRR. Two-fold cross-validation repeated 10,000 times was used to assess the predictive performance of the best model. Statistical analysis was done with SAS version 9 (SAS Institute, Cary, NC) and S-Plus version 7 (Insightful Co., Seattle, WA). Receiver operating characteristic (ROC) curves were generated for each model. The area under the curves (AUC) was determined for each and the corresponding values compared.

Results

The patient characteristics are summarized in Table 1. The prescription dose range was between 45 and 60.6 CGE (median 50.4 CGE) over 28 fractions. The mean lung dose range was 1.0–13.4 CGE (median 5.5 CGE) for all patients. The percent of lung receiving >5 CGE (V_5) was 3.40–59.9% (median 25.4%). The percent receiving >10 CGE (V_{10}) was 2.76–48.7% (median 21.1%). The percent receiving >20 CGE (V_{20}) was 1.18–30.91% (median 10.9%). The interval time from completion of proton radiotherapy until PET/CT imaging was between 21 and 86 days (median 39 days). Patients who received PET/CT less than 20 or greater than 90 days were excluded. There was no significant correlation between the time interval to PET and the resulting mean SUV. The CTCAE v4 scores for pneumonitis were as follows: 36 (36.0%) patients with grade 0; 37 (37.0%) patients with grade 1; 20 (20.0%) patients with grade 2; 7 (7.0%) patients with grade 3. There were no patients (0.0%) with grade 4 or 5 toxicity. Patients who had a toxicity score of 2 or greater were characterized as symptomatic ($n = 27$) and comprised 27% of study subjects. The mean dosimetric parameters for the symptomatic and asymptomatic groups are found in Table 2.

Registered planning CT and PET CT were used to correlate SUV with dose for each patient (Fig. 1). The mean SUV value for the lung receiving between 0 and 10 CGE was 0.64, 10–20 CGE was 0.78, 20–30 CGE was 0.88, 30–40 CGE was 0.94 and 40–50 CGE was 1.02 with an overall median SUV of 0.83. The average SUV uptake for lung treated in symptomatic patients vs. asymptomatic patients was 0.98 and 0.86 respectively ($p = 0.02$). To test the hypoth-